Mutual of America Capital Management LLC Decreases Stock Holdings in Medpace Holdings, Inc. $MEDP

Mutual of America Capital Management LLC reduced its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 12.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,250 shares of the company’s stock after selling 1,472 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Medpace were worth $5,270,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Wasatch Advisors LP raised its stake in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares during the last quarter. Mawer Investment Management Ltd. increased its holdings in Medpace by 17.4% during the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after purchasing an additional 121,213 shares during the period. AQR Capital Management LLC increased its holdings in Medpace by 15.1% during the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock valued at $193,269,000 after purchasing an additional 81,637 shares during the period. Baillie Gifford & Co. raised its position in Medpace by 12.0% during the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after purchasing an additional 62,503 shares during the last quarter. Finally, TD Asset Management Inc lifted its holdings in Medpace by 15.6% in the 2nd quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock worth $143,636,000 after buying an additional 61,764 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on MEDP. Barclays boosted their target price on Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research report on Friday, October 31st. Mizuho set a $660.00 price objective on shares of Medpace in a report on Friday, January 9th. Robert W. Baird set a $613.00 target price on shares of Medpace in a research report on Friday, October 24th. Finally, Truist Financial set a $555.00 price target on shares of Medpace in a research report on Monday, October 27th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $491.27.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $597.91 on Thursday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92. The firm has a 50-day moving average of $584.33 and a 200 day moving average of $527.06. The stock has a market cap of $16.84 billion, a P/E ratio of 41.81, a price-to-earnings-growth ratio of 2.02 and a beta of 1.43.

Insider Activity

In other news, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. The trade was a 42.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 59,025 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the transaction, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. This trade represents a 7.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 341,695 shares of company stock worth $205,718,239. Insiders own 20.30% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.